---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-030286"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2026-06-26T20:05:40+00:00"
generated_at: "2026-06-26T20:08:02.200097+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BriaPro subsidiary reports 9-month net loss of $712K; going concern uncertainty

## Summary
- Net loss for 9 months ended April 30, 2026: $712,236, vs $519,804 in prior-year period.
- Accumulated deficit of $1,892,661; cash $299,950 vs $1 at July 31, 2025.
- Acquired sCD80 license from parent BriaCell for 23,972,589 shares valued at $846,532.
- Due to related parties (BriaCell) $2,093,345; going concern depends on parent financing.
- R&D expenses $649,991; granted 7,189,000 RSUs to directors on April 1, 2026.

## SEC filing metadata
- accession: 0001493152-26-030286
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2026-06-26T20:05:40+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/0001493152-26-030286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-030286
- JSON: https://secwatch.observer/filing/0001493152-26-030286.json
- Plain text: https://secwatch.observer/filing/0001493152-26-030286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.